^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Belrapzo (bendamustine RTD) (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/14/2021
    Excerpt:
    BELRAPZO is an alkylating drug indicated for treatment of patients with…Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.